XML 86 R64.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets and Goodwill - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jul. 02, 2024
Sep. 26, 2023
Goodwill [Line Items]            
Amortization and impairment of acquired intangible assets $ 130,300,000 $ 60,900,000 $ 295,500,000 $ 164,000,000.0    
Impairment of intangible assets 20,200,000 0 20,200,000 0    
Accumulated impairment losses related to goodwill $ 0   $ 0      
Acquired and in-licensed rights and patents            
Goodwill [Line Items]            
Weighted-Average remaining useful life 13 years   13 years      
Acquired and in-licensed rights and patents | Minimum            
Goodwill [Line Items]            
Estimated life (in years) 2 years   2 years      
Acquired and in-licensed rights and patents | Maximum            
Goodwill [Line Items]            
Estimated life (in years) 21 years   21 years      
Developed technology and other            
Goodwill [Line Items]            
Weighted-Average remaining useful life 10 years   10 years      
Developed technology and other | Minimum            
Goodwill [Line Items]            
Estimated life (in years) 13 years   13 years      
Developed technology and other | Maximum            
Goodwill [Line Items]            
Estimated life (in years) 31 years   31 years      
Completed Technology | Minimum            
Goodwill [Line Items]            
Estimated life (in years) 2 years   2 years      
Completed Technology | Maximum            
Goodwill [Line Items]            
Estimated life (in years) 31 years   31 years      
Reata Pharmaceuticals, Inc            
Goodwill [Line Items]            
Impairment of intangible assets $ 110,100,000 $ 60,900,000 $ 275,300,000 $ 164,000,000.0    
Reata Pharmaceuticals, Inc | In-process research and development            
Goodwill [Line Items]            
Intangible assets: 2,300,000,000   2,300,000,000     $ 2,300,000,000
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)            
Goodwill [Line Items]            
Intangible assets: 4,200,000,000   4,200,000,000     4,200,000,000
Reata Pharmaceuticals, Inc | Priority review voucher            
Goodwill [Line Items]            
Intangible assets: 100,000,000.0   100,000,000.0     $ 100,000,000
Human Immunology Biosciences            
Goodwill [Line Items]            
Intangible assets:         $ 1,600,000,000  
Human Immunology Biosciences | In-process research and development            
Goodwill [Line Items]            
Intangible assets: $ 1,600,000,000   $ 1,600,000,000